To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT00191191 · COMPLETED
Trial details
- NCT number
- NCT00191191
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2004-10-01
- Primary completion
- 2008-10-01
- Enrollment
- 226
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.